Notícias e Atividades da Beckley Psytech

A Beckley Psytech pertence à AtaiBeckley.

AtaiBeckley é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

AtaiBeckley é uma empresa listada sob o símbolo ATAI (DE).

AtaiBeckley tem presença direta em 2 países.

Fusão, aquisição e financiamento envolvendo AtaiBeckley.

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).

Veja o organograma con seus 7 executivos principais

Biografias mais buscadas da Beckley Psytech

• Cosmo Mellen, Chief Executive Officer
• Rob Hershberg, Director
• Gerd Kochendoerfer, Director

Recentes movimentos de executivos em AtaiBeckley

• Anne Johnson antes Chief Financial Officer, agora é Chief Accounting Officer  (Notícia publicada em 19 de fevereiro de 2026).
• Michael Faerm, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 19 de fevereiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Beckley Psytech.

AtaiBeckley possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Beckley Psytech

• atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
• atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
• Beckley Psytech announces positive topline data from Part 2 of its Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) in combination with SSRIs for treatment resistant depression
• News
• Beckley Psytech Completes Enrolment in Phase IIb study of BPL-003 for Treatment Resistant Depression
• Beckley Psytech announces positive topline results from Phase IIa study of ELE-101 (IV psilocin benzoate) for Major Depressive Disorder
• Publications
• Beckley Psytech announces initial results from Phase I study and first patients dosed in Phase IIa study of ELE-101 (IV psilocin benzoate) for Major Depressive Disorder
• First patient dosed in Beckley Psytech’s Phase IIa study of BPL-003 in combination with SSRIs for Treatment Resistant Depression
• Beckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression
• View more press releases Close

Redes sociais sobre Beckley Psytech

• Beckley Psytech na Wikipedia, Google News e Yahoo Finance
• Beckley Psytech na LinkedIn, X (Twitter) e YouTube